Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases
about
sameAs
Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentShould aspirin be used to counteract 'salicylate deficiency'?A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugsAntiplatelet therapy and spontaneous perirenal hematomaPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinUpper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapyAdverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tractReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Combining aspirin with antithrombotic agentsAn economic model of long-term use of celecoxib in patients with osteoarthritisIncidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery diseaseInteraction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseasesA prospective study of aspirin use and the risk of gastrointestinal bleeding in menGender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients.Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery DiseaseImpact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirinLong-term use of aspirin and the risk of gastrointestinal bleeding.Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissectionUse of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.Hospital physicians' influence on gastrointestinal protection during treatment with non-steroidal anti-inflammatory drugs and acetylsalicylic acid and the impact on prescribing in primary care.Analgesic activity of fixed dose combinations of paracetamol with diclofenac sodium and paracetamol with tramadol on different pain models in healthy volunteers - A randomized double blind crossover studyStudy of Clinical and Genetic Risk Factors for Aspirin-induced Gastric Mucosal InjuryImproving the gastrointestinal tolerability of aspirin in older people.Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin ConsumersCost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran.Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.Gastrointestinal bleeding after percutaneous coronary intervention.Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.Aspirin for cardioprotection and strategies to improve patient adherence.Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study.Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment.Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.Upper gastrointestinal complications induced by anti-platelet agents.Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.Time trends in incidence of peptic ulcer bleeding and associated risk factors in Norway 1985-2008.Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: a randomized, double-blinded, placebo controlled study.
P2860
Q27027977-A16CECA4-3267-4463-B4BB-B31F920862E5Q28166200-AA75B6B8-2697-41E4-8F95-824665C2E6A8Q28176840-CC0A9C55-2C61-4979-9F93-B32425FAAD25Q28177025-455E7106-71F3-4C7D-A06B-CF93DC674EE4Q28192701-39CB76D6-FCFB-4EEE-A00F-3DAFC891F055Q28194669-993470D5-0168-408A-9CEB-D754A2F50202Q28199102-6858B01A-4AF6-4DF9-8AC2-768B14217637Q28200403-1F44349A-21BC-4EA2-95D4-562D7953F8ABQ28200615-909B33E9-9BD8-4A3C-B0FC-97E0C05D7D2EQ28218005-F9720C65-A241-4617-BE0F-C39AB77892C0Q28218326-9C794C0D-C7C8-4A56-A68F-6B9A07933334Q28219634-41523E1F-E430-471D-BE92-42A622B570CDQ28743884-1394A326-7850-4B9B-B389-841C748CE62FQ33798895-D5004C69-BB50-4943-A0A1-AAD30E7224C6Q33855588-F400F7A9-3CFA-4828-81C2-7CF08A0CAABBQ34177563-00E0BD66-BCD2-4932-8E80-6251577B9B0EQ34628874-5347CEEF-83DB-4913-86F7-628AE2576609Q34935769-FFCF4D23-FC5A-4F6D-BDA0-368DE12C2CA5Q34980127-2A87B4E1-6B84-467C-8E2D-6DB8328F94D5Q35026319-EA270889-E503-4B1E-BB61-81A979DE577DQ35069807-79A90038-EEC5-4F98-8138-275C380AE557Q36439268-A9915203-D58B-4929-9070-094DD3B91657Q36705464-0737D577-BDDA-42D4-8086-EA10EE7CF1F5Q37019062-D66CAAF9-FD4C-4704-9675-DE8921A33D24Q37192996-C1E38CBC-E49B-4C16-9217-8CCC8C7E07D8Q37743623-13387F17-272D-4204-BEB3-896DBAFA12F4Q37774375-93B90DD3-3D70-4122-A940-51BD871C51F3Q37832368-48ABDD37-03C1-4A91-8BCD-575A9B7BE9B2Q37903846-6BE3CD81-37D8-47BD-93B1-4836D5A4855AQ38001074-E2E4DCAD-95E4-4E2D-B899-8E3D3DB7F970Q38176141-D2D885BB-A83F-4574-B3B2-F33D7A5747E9Q38321114-9A6D7866-8259-4ACD-A278-8A17781F9EFCQ38439626-C824027D-4109-437B-82AE-41CFAEB6248DQ38809179-0B864D4A-81E8-4DCA-BE35-FF9B5F97D25CQ39305541-8821037B-DEA2-48C0-BD6A-7D7D6E2947C5Q39746156-3BEEDCA3-66ED-4401-AEB4-71886EACC895Q40729160-324C6623-D829-4E6B-8C1F-0CCA02EC2A80Q41532376-89D1AFB8-F300-4E4D-90F4-5CE84D1DAEAFQ42731841-108971F2-FF22-4C00-8E68-EC2AF94B2C71Q42873633-80698AC2-A888-4DD6-955B-4B268A72B34E
P2860
Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@ast
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@en
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@nl
type
label
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@ast
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@en
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@nl
prefLabel
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@ast
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@en
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@nl
P2093
P2860
P921
P3181
P1476
Risk of upper gastrointestinal ...... ion of cardiovascular diseases
@en
P2093
P2860
P304
P3181
P356
10.1046/J.1365-2036.2002.01355.X
P407
P577
2002-11-01T00:00:00Z